Vasoreactivity in Carriers of Genetic Polymorphisms

• Status: Unknown status
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to assess the impact of genetic variation (especially polymorphisms of the gene coding endothelial nitric oxide synthase (eNOS) and the bradykinin B2 receptor gene) on venous and arterial responsiveness to vasodilators in healthy individuals without cardiovascular risk factors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Heidelberg University
• Treatments: Acetylcholine; Bradykinin; Kininogens; Nitroprusside

Criteria

Inclusion Criteria:

• age: 18 - 70

• gender: male

• good state of health

Exclusion Criteria:

• known condition causing endothelial dysfunction (e.g. diabetes, hyperlipidaemia, arterial hypertension, smoking, homocysteinemia)

• regular medication and/or treatment with drugs within the last 4-6 weeks (exclusion has to be decided in each case)

• acute or chronic illness

• methylxanthines and alcohol during 12 hours before the study

• nicotine during 1 year before the study

• drug and/or alcohol abuse

• pregnancy or lactation